Biosergen AB (publ) (8N1.F), Thursday announced the appointment of Mark Beveridge as its new Chief Financial Officer, succeeding Niels Laursen, who will remain with the company to ensure a smooth transition.
Recently, Beveridge serves as Vice President Finance at Moberg Pharma. He plans to continue in this role alongside his new responsibilities at Biosergen.
Tine Olesen, CEO of Biosergen, commented, "Mark's experience will be highly valuable as we continue our mission to develop life-saving antifungal therapies for patients with an unmet medical need."
Currently, Biosergen's stock is moving down 5.86 percent, to 0.0450 euros on the Frankfurt.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.